GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Porton Pharma Solutions 300363.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

23.65

-2.35%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥3.42bn

FY2016FY2025

Net income

CN¥96.3m

FY2016FY2025

Free cash flow

CN¥464.4m

FY2016FY2025

Shareholders' equity

CN¥5.35bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥3.42bnCN¥3.01bnCN¥3.67bnCN¥7.03bnCN¥3.11bnCN¥2.07bnCN¥1.55bnCN¥1.18bnCN¥1.18bnCN¥1.33bn
Gross profitCN¥1.02bnCN¥702.6mCN¥1.44bnCN¥3.64bnCN¥1.26bnCN¥835.0mCN¥549.9mCN¥389.9mCN¥428.6mCN¥500.0m
Research and developmentCN¥267.6mCN¥338.5mCN¥452.2mCN¥519.5mCN¥263.8mCN¥157.8mCN¥122.6mCN¥76.2mCN¥75.3mCN¥72.6m
Operating incomeCN¥125.5m−CN¥334.4mCN¥268.9mCN¥2.27bnCN¥565.6mCN¥355.5mCN¥194.7mCN¥154.0mCN¥163.3mCN¥232.4m
Net incomeCN¥96.3m−CN¥287.8mCN¥266.9mCN¥2.01bnCN¥523.9mCN¥324.4mCN¥185.6mCN¥124.5mCN¥107.4mCN¥171.2m
Diluted earnings per share0.18-0.530.493.740.960.590.350.230.240.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥8.55bnCN¥8.82bnCN¥9.38bnCN¥10.14bnCN¥6.56bnCN¥4.50bnCN¥3.96bnCN¥4.37bnCN¥2.85bnCN¥2.87bn
Cash and short-term investments—CN¥1.47bnCN¥1.97bnCN¥2.85bnCN¥1.22bnCN¥1.27bnCN¥1.17bnCN¥2.06bnCN¥307.6mCN¥458.6m
Total liabilitiesCN¥3.05bnCN¥3.40bnCN¥3.28bnCN¥3.67bnCN¥2.38bnCN¥1.10bnCN¥891.2mCN¥1.49bnCN¥1.40bnCN¥1.50bn
DebtCN¥481.3mCN¥1.57bnCN¥1.71bnCN¥923.8mCN¥740.8mCN¥412.6mCN¥347.4mCN¥1.15bnCN¥958.0mCN¥1.04bn
Shareholders' equityCN¥5.35bnCN¥5.20bnCN¥5.80bnCN¥6.00bnCN¥3.98bnCN¥3.39bnCN¥3.07bnCN¥2.88bnCN¥1.38bnCN¥1.28bn
Shares outstanding542m543m546m536m546m551m535m550m441m434m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥757.0mCN¥405.5mCN¥629.1mCN¥2.56bnCN¥480.2mCN¥504.4mCN¥351.4mCN¥193.6mCN¥289.5mCN¥285.3m
Capital spending−CN¥292.6m−CN¥490.6m−CN¥1.13bn−CN¥1.17bn−CN¥777.0m−CN¥394.0m−CN¥175.1m−CN¥168.1m−CN¥158.7m−CN¥188.6m
Free cash flowCN¥464.4m−CN¥85.1m−CN¥500.8mCN¥1.39bn−CN¥296.8mCN¥110.4mCN¥176.3mCN¥25.5mCN¥130.8mCN¥96.8m
Dividends paid−CN¥30.1m−CN¥301.5m−CN¥626.6m−CN¥105.0m−CN¥65.4m−CN¥55.8m−CN¥25.1m−CN¥74.4m−CN¥76.0m−CN¥55.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥903.8mCN¥886.0mCN¥875.4mCN¥923.5mCN¥819.8mCN¥801.2mCN¥886.7mCN¥773.2m
Gross profitCN¥305.8mCN¥271.1mCN¥289.6mCN¥286.5mCN¥236.8mCN¥211.0mCN¥207.8mCN¥260.9m
Operating incomeCN¥88.1mCN¥51.4mCN¥62.5mCN¥44.0mCN¥25.5m−CN¥3.8m−CN¥48.3m−CN¥24.1m
Net income−CN¥252.1mCN¥27.9mCN¥16.4mCN¥52.9mCN¥31.3m−CN¥4.3m−CN¥81.3m−CN¥36.4m
Diluted earnings per share-0.460.050.030.100.06-0.01-0.15-0.07
Cash from operations———CN¥126.0mCN¥164.0mCN¥85.0m—CN¥65.0m
Capital spending−CN¥30.0m−CN¥18.0m−CN¥3.0m−CN¥58.0m−CN¥121.0m−CN¥109.0m−CN¥75.0m−CN¥111.0m
Free cash flow———CN¥68.0mCN¥43.0m−CN¥24.0m—−CN¥46.0m
Total assetsCN¥7.85bnCN¥8.48bnCN¥8.55bnCN¥8.58bnCN¥8.70bnCN¥8.65bnCN¥8.82bnCN¥8.92bn
Cash and short-term investments———CN¥1.33bnCN¥1.54bnCN¥1.44bnCN¥1.47bnCN¥1.40bn
DebtCN¥493.6mCN¥428.0mCN¥481.3mCN¥832.6mCN¥794.1mCN¥979.8mCN¥975.0mCN¥1.07bn
Shareholders' equityCN¥4.96bnCN¥5.36bnCN¥5.35bnCN¥5.33bnCN¥5.29bnCN¥5.21bnCN¥5.20bnCN¥5.31bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin29.9%23.3%39.2%51.7%40.6%40.3%
Operating margin3.9%-11.1%7.3%32.2%18.2%17.2%
Net margin2.8%-9.6%7.3%28.5%16.9%15.7%
Return on equity1.8%-5.5%4.6%33.4%13.2%9.6%
Return on assets1.1%-3.3%2.8%19.8%8.0%7.2%
Free cash flow yield7.9%6.7%13.1%28.4%9.4%6.6%
Revenue growth13.5%-17.9%-47.9%126.6%49.9%33.6%
Earnings growth-133.5%-207.8%-86.7%282.8%61.5%74.8%
Current ratio1.82x1.90x2.63x1.81x1.52x2.22x
Debt to equity0.09x0.19x0.19x0.10x0.13x0.07x
Equity ratio62.6%59.0%61.8%59.2%60.7%75.4%
Interest coverage2.64x-5.25x5.76x65.74x24.37x13.84x
R&D as a share of sales7.8%11.2%12.3%7.4%8.5%7.6%
Buybacks as a share of market value0.1%0.6%-1.9%1.8%0.9%-2.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-21.4%10.5%12.8%
Operating income-61.9%-18.8%-0.3%
Net income-63.6%-21.6%-1.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin26.8%39.7%39.9%38.8%
Operating margin-3.2%13.6%14.5%14.4%
Net margin-3.0%12.1%13.1%12.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings130.8-29.851.510.993.262.041.339.254.550.8
Price to sales3.72.83.83.115.79.74.94.15.06.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 12 May 2026.

FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.090.4871.1060.1930.1210.1040.0470.026
  • 3-for-2 split · 29 Sept 2015
  • 5-for-2 split · 26 Mar 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.